Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers

(2011) Miyako Kishimoto et al.   Cardiovascular Diabetology

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES

Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients

(2011) T. Narita et al.   DIABETES OBESITY & METABOLISM

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

(2011) Daisuke Yabe et al.   Journal of Diabetes Investigation

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

(2009) Bo Ahrén et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

(2008) Avraham Karasik et al.   CURRENT MEDICAL RESEARCH AND OPINION

Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients

(2008) T. Narita et al.   DIABETIC MEDICINE

Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes

(2008) J. Foley et al.   HORMONE AND METABOLIC RESEARCH

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

(2008) Debora Williams-Herman et al.   BMC Endocrine Disorders